PP_1170x120_10-25-21

Sun Pharma donates medicines and hand sanitizers to support India’s COVID-19 pandemic response

Print Friendly, PDF & Email

MUMBAI, India — Sun Pharmaceutical Industries announced its commitment to donate INR 250 Million (Indian Rupees Two Hundred and Fifty Million) of Hydroxychloroquine (HCQS), Azithromycin, other related drugs and hand sanitizers to support India’s COVID-19 pandemic response.

Sun Pharma salutes the entire medical & support fraternity including doctors, nurses and healthcare workers who are selflessly providing care to all affected patients in India. To help these front-line warriors, the company has re-purposed its liquid manufacturing facility in India to produce high-quality hand sanitizers and will make them available to health care professionals serving their communities and the nation.

Sun Pharma is committed to fight the COVID-19 pandemic and has instituted work from home for all team members who are able to work remotely at all its locations. The company is proud of its passionate and dedicated team members in Manufacturing, IT, Quality, Finance, HR and Supply Chain, who are ensuring continued supply of medicines to address the needs of patients.

Sun Pharma urges people both in India and around the world not to hoard medicines, in order to make sure they are available to those in genuine need. The company is committed to working closely with the governments and relevant stakeholders to ensure there is un- interrupted supply of medicines. Sun Pharma is constituting a task force to handle the distribution of these products in India.

The National Task Force1 for COVID-19 has recommended the prophylactic use of HCQS for high risk population2. The approved indications of HCQS are malaria, lupus erythematosus and rheumatoid arthritis. The approved indications of Azithromycin are Uncomplicated Skin/Skin Structure Infections, Community-Acquired Pneumonia, etc. HCQS is currently being studied by the World Health Organization (WHO) for use in-conjunction with Azithromycin to treat COVID-19.


ECRM-08-202222

Adheris Health

Comments are closed.

Adheris Health